

#26
LP

Attorney Docket No.: 6004,200-US

. PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Belguith et al.

Application No.: 09/383,318

Group Art Unit: 1652

Filed: August 26, 1999

Examiner: Slobodyansky

For: Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same

PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(a)

Box DAC
Commissioner for Patents
Washington, DC 20231

Sir:

On behalf of the Assignee hereof and of the inventors, the undersigned hereby petitions to change the inventorship in the above-captioned application by deleting Monia Mezghani from the recorded list of inventors.


In support of this petition, enclosed are the following:

- a. A statement by Monia Mezghani that the error arose inadvertently and without deceptive intent;
- b. A newly executed oath/declaration by all of the actual inventors;
- c. A statement from Novozymes A/S, the assignee, agreeing to the change of inventorship in the above-captioned application; and
- d. Authorization to charge the petition fee set forth in 37 CFR 1.17(i) (currently \$130.00) to Deposit Account No. 50-1701.

Accordingly, the undersigned respectfully requests that this petition be granted.
A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 2, 2001



Jason I. Garbell, Reg. No. 44,116
Navozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 6004.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Belguth et al.

Application No.: 09/383,318

Group Art Unit: 1652

Filed: August 26, 1999

Examiner: Slobodyansky

For: Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same

STATEMENT BY MONIA MEZGHANI UNDER 37 C.F.R. § 1.48(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I, Monia Mezghani, hereby state that:

1. Although my name was initially included in the list of inventors of the above-referenced application, I am not an inventor of the subject matter claimed in the above-referenced application.
2. My contribution to the claimed invention included sequencing the nucleic acid sequence of the glucose isomerase gene disclosed and claimed in the above-referenced application. As a result of this contribution, it was initially decided that I was properly named as an inventor of the above-referenced application. Upon further consideration, however, it has been decided that I am not properly named as an inventor because the other inventors had possession of the gene encoding the glucose isomerase of the above-referenced application before my contribution.
3. According, the addition of my name to the list of named inventors was an error that occurred inadvertently and without deceptive intent on my part.

Monia Mezghani

Date: 01-11-2001

#25
A

Attorney Docket No.: 6004,200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Belguith et al.

Application No.: 09/383,318

Group Art Unit: 1652

Filed: August 26, 1999

Examiner: Slobodyansky

For: Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same

CONSENT BY ASSIGNEE UNDER 37 C.F.R. § 1.48(a)

Commissioner for Patents
Washington, DC 20231

Sir:

Each of the originally named inventors is obligated to assign their rights to Novozymes A/S, a corporation formed under the laws of the Kingdom of Denmark. An assignment by the originally named inventors was recorded on December 20, 1999, at Reel 010493, Frame 0528. Novozymes A/S consents to the change of inventorship in the above captioned application comprising the deletion of Monia Mezghani from the recorded list of inventors.

Date: 30 October 2001

Gertrud Sonne Kofoed
Gertrud Sonne Kofoed